CDH2 and cancer: During EMT process, the conversion of E-cadherin to N-cadherin reduces the expression of human balanced nucleoside transporter 1 (hENT1), a drug carrier for gemcitabine membrane transport in cancer cells, which triggers gemcitabine resistance in cancer cells (Weadick et al., 2021).